Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071956
Filing Date
2025-05-15
Accepted
2025-05-15 07:00:22
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q grtx-20250331.htm   iXBRL 10-Q 1281977
2 EX-10.3 grtx-ex10_3.htm EX-10.3 29209
3 EX-31.1 grtx-ex31_1.htm EX-31.1 16111
4 EX-31.2 grtx-ex31_2.htm EX-31.2 17666
5 EX-32.1 grtx-ex32_1.htm EX-32.1 9031
6 EX-32.2 grtx-ex32_2.htm EX-32.2 8052
  Complete submission text file 0000950170-25-071956.txt   6401320

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT grtx-20250331.xsd EX-101.SCH 1082582
70 EXTRACTED XBRL INSTANCE DOCUMENT grtx-20250331_htm.xml XML 978286
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39114 | Film No.: 25948618
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)